Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]Flonoltinib Maleate in Healthy Subjects
NCT07612306Phase 1Completed
- Sponsor
- Zenitar
- Start
- Jul 2026
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of flonoltinib, sponsored by Zenitar. Primary endpoints: Cumulative excretion rate of total radioactivity in urine and feces at 360 hours, Identify the main metabolites at 216 hours and 1 more. Started Jul 2026; status: completed.
02
Drugs
flonoltinib
Beyond the preview
Go deeper on NCT07612306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07612306.